TG Therapeutics, Inc. Announces Data Presentations at the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting

Combination of TG-1101, the Company's Novel Glycoenginereed Anti-CD20 Monoclonal Antibody and TGR-1202, the Company's Once Daily PI3K Delta Inhibitor to be Highlighted in Oral Presentation

Updates on the Combination of TG-1101 Plus Ibrutinib, and Single-Agent TGR-1202 to be Featured in Poster Presentations

TG Therapeutics to Host a Reception on Monday December 8 th from 7:45 pm – 9:00 pm with Presentations by Leading Clinical Investigators

NEW YORK, Nov. 6, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq: TGTX ) today announced that updated data for TG-1101 (ublituximab), the Company's novel, glycoengineered anti-CD20 monoclonal antibody, and TGR-1202, the Company's PI3K delta inhibitor, has been selected for presentation at the upcoming 56 th American Society of Hematology Annual Meeting (ASH), to be held December 6 -9, 2014, at the Moscone Center, in San Francisco, CA. Key data from the Company's proprietary combination of TG-1101 and TGR-1202 trial in patients with chronic lymphocytic leukemia (CLL), and non-Hodgkin's lymphoma (NHL) will be presented in an oral presentation. In addition, poster presentations will include updates from the ongoing combination trial of TG-1101 plus ibrutinib, as well as from the ongoing single agent trial of TGR-1202.

Presentations on TG-1101 and TGR-1202 at the ASH meeting include the following:

Oral Presentation:

  • Title: Ublituximab, A Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), In Combination With TGR-1202, A Next Generation Once Daily PI3k delta Inhibitor, Demonstrates Activity In Heavily Pre-Treated And High-Risk CLL And B-Cell Lymphoma
    • Oral Session: 801
    • Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Indolent B-cell NHL and T-cell NHL
    • Date and Time: Tuesday, December 9, 2014 at 8:00am, during 7:30 – 9:00 AM Session
    • Location: West Building, 2005-2007-2018-202
    • Presenter: Matthew Lunning, DO

Clinical Posters:

  • Title: TGR-1202, A Novel Once Daily PI3K delta Inhibitor, Demonstrates Clinical Activity With A Favorable Safety Profile, Lacking Hepatotoxicity, In Patients With CLL And B-Cell Lymphoma
    • Abstract Number: 1984
    • Session: 642. CLL: Therapy, excluding Transplantation: Poster I
    • Date and Time: Saturday, December 6, 2014: 5:30 PM- 7:30 PM
    • Location: West Building, Level 1
    • Presenter: Howard A. Burris III, MD
  • Title: Ublituximab (TG-1101), A Novel Glycoengineered Anti-CD20 Monoclonal Antibody, In Combination With Ibrutinib Is Highly Active In Patients With Relapsed and/or Refractory CLL And MCL; Results Of A Phase II Trial
    • Abstract Number: 4679
    • Session: 642. CLL: Therapy, excluding Transplantation: Poster III
    • Date and Time:  Monday, December 8, 2014: 6:00 PM- 8:00 PM
    • Location: West Building, Level 1
    • Presenter: Jeff P. Sharman, MD

Pre-Clinical Posters:

  • Title: Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-KappaB in Models of B- and T-Cell Lymphoma
    • Abstract Number: 1770
    • Session: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster I
    • Date and Time:  Saturday, December 6, 2014: 5:30 PM-7:30 PM
    • Location: West Building, Level 1
    • Presenter: Changchun Deng, MD, PhD
  • Title: The PI3K-delta Inhibitor TGR-1202 In Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts
    • Abstract Number: 4486
    • Session: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster III
    • Date and Time:  Monday, December 8, 2014: 6:00 PM-8:00 PM
    • Location: West Building, Level 1
    • Presenter: Silvia L. Locatelli, PhD

A copy of the above referenced abstracts can be viewed online through the ASH meeting website at www.hematology.org .

TG Therapeutics will also host a reception on Monday, December 8 th , 2014 with featured presentations beginning at 8:00pm. Presenters will include: Jeff Sharman, MD, with US Oncology Research, Nathan Fowler, MD, with MD Anderson Cancer Center, Matthew Lunning, DO, with University of Nebraska Medical Center and Owen O'Connor, MD, PhD, with Columbia University Medical Center. The event will take place at the San Francisco Marriott Marquis. This event will be webcast and will be available on the Events page, under the Investors & Media tab, of the Company's website at www.tgtherapeutics.com .

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for cancer and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop IRAK4 inhibitors. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials, the timing of commencing, completing or reporting such trials, the business prospects for TG-1101 and TGR-1202, the potential benefits of combining TG-1101 and TGR-1202may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101 and TGR-1202; the risk that early pre-clinical and clinical results that supported our decision to move forward with TG-1101 and TGR-1202 will not be reproduced in additional patients or in future studies; the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following the completion of the current phase 1 study; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that hepatotoxicity will be observed in current or future studies; the risk that our ongoing or contemplated drug combinations may not prove tolerable or efficacious; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at  www.tgtherapeutics.com . The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

TGTX-G

Jenna Bosco Director- Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 0

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 202

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 49

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 24

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 28

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 89

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 83

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 42

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 38

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring High ROIC Tech Stocks: Key Insights and Analysis

Updated Category News Views 284

Understanding ROIC in Tech Stocks Return on Invested Capital (ROIC) is a vital indicator when evaluating a company's financial performance and investment potential. It reflects how efficiently a firm uses the capital invested by shareholders to generate profits. High ROIC values signal that a company is not only effective in utilizing its resources but may also be poised...

Continue Reading
Join AVITA Medical's Upcoming Investor Webinar Event

Updated Category News Views 141

AVITA Medical Plans Informative Investor Webinar AVITA Medical, Inc. (NASDAQ: RCEL), known for its innovative approaches to acute wound care, is gearing up to host an insightful investor webinar. The CEO, Jim Corbett, alongside CFO, David O'Toole, will lead this engaging session and discuss the latest financial results and strategic business developments. Details of the...

Continue Reading
Labour Government's Budget Aims to Restore Market Stability

Updated Category News Views 138

Introduction to the New Labour Budget The newly formed Labour government has introduced its first budget, aiming to restore confidence in the UK markets. With a focus on substantial tax increases and strategic spending control, this budget seeks to avoid the destabilizing impact seen during Liz Truss's tenure. The measures announced are designed to bolster the economy...

Continue Reading
Beacon Energy to Host Annual General Meeting This December

Updated Category News Views 166

Beacon Energy's Annual General Meeting Update Beacon Energy plc (AIM: BCE, NYSE: BCE) is an oil and gas company dedicated to developing its onshore assets in Germany. Recently, the company confirmed that it is set to hold its Annual General Meeting (AGM) on December 18, 2024. This significant event will be hosted at 55 Athol Street, Douglas, Isle of Man, providing a prime...

Continue Reading
Okeanis Eco Tankers: Key Insights Ahead of Earnings Call

Updated Category News Views 130

Anticipating Okeanis Eco Tankers' Upcoming Earnings Okeanis Eco Tankers (NYSE:ECO) is preparing to release its latest quarterly earnings report soon. Investors and analysts are keenly focused on what this announcement will bring, particularly in terms of earnings expectations and guidance for upcoming quarters. Expected Earnings Report Industry analysts anticipate that...

Continue Reading